Published: June 09, 2010
Xcellerex Announces Groundbreaking for New State-of-the-Art FlexFactory Biomanufacturing Facility
MARLBOROUGH, Mass. - (BUSINESS WIRE) - Xcellerex, Inc. announced today that it has begun construction of a
state-of-the-art cGMP FlexFactory biomanufacturing facility at its
headquarters location in Marlborough, Massachusetts. Construction will
be completed in September 2010. The facility, the second FlexFactory at
the company's headquarters site, will expand Xcellerex's capacity to
provide bridge biomanufacturing services for clients that are planning
or building their own FlexFactory facilities. The plant will also
support Xcellerex's contract manufacturing operations.
Xcellerex President and CEO Guy Broadbent commented, "This facility
represents an important milestone for Xcellerex. First, it reflects the
surge in interest we are seeing in the FlexFactory platform. The new
plant will enable our biomanufacturing services group to support the
increased demand for transitional biomanufacturing that we offer to help
speed client deployments of their new FlexFactory installations. Second,
this will provide a working showcase to demonstrate FlexFactory to the
many customers who have expressed interest in evaluating the platform
for their next capacity investment." Finally, he noted, "The timeline in
which we will bring this cGMP facility online will dramatically
underscore the leap in deployment speed that FlexFactory enables."
Xcellerex founder and Chief Technology Officer Parrish Galliher added,
"This new FlexFactory facility in Marlborough will be a great case
study, demonstrating the power of the FlexFactory capability. We will
achieve new working capacity in less than six months, at a fraction of
the cost required for a conventional facility. This will also give us a
hands-on educational tool to help prospective customers achieve a deeper
understanding of how a FlexFactory operates."
The new facility will feature 2,000 liter Xcellerex XDR single-use
bioreactors and modular single-use downstream unit operations through
bulk-product.
About FlexFactory
Xcellerex's FlexFactory is an innovative, portable manufacturing
platform, based on the innovative application of (1) single-use
technologies; (2) controlled environmental modules (CEMs); and (3)
advanced and proven process automation including electronic batch
records. The FlexFactory effectively eliminates clean- and
steam-in-place and clean room infrastructure; greatly simplifies
facility design, reducing manufacturing footprint and capital
investment; and creates breakthrough gains in operating efficiency,
flexibility and environmental friendliness.
About Xcellerex, Inc.
Xcellerex is revolutionizing the way biomolecules are developed,
manufactured and commercialized. The company's unique single-use
component technology platform transforms biomanufacturing economics,
enabling the development of biotherapeutics and vaccines, and
dramatically improving the ability of Xcellerex and its partners to
deploy manufacturing capacity. Xcellerex leverages its technology and
services platform by: 1) commercializing its FlexFactories (complete,
turnkey, modular production trains) and XDR (unique, single-use
component bioreactor systems); 2) building a portfolio of proprietary
biotherapeutics and vaccines through creative alliances and in
licensing; and 3) creatively structuring transactions around
FlexFactories, XDRs and its pipeline. Based in Marlborough,
Massachusetts, Xcellerex is backed by an experienced management team and
top-tier venture investors including Kleiner Perkins Caufield & Byers,
VantagePoint Venture Partners and SCG Capital. For more information,
please visit the company's website at http://www.xcellerex.com
Xcellerex, Inc.
Ted Marple, 508-683-2253
Vice President of
Business Development
or
RMG Associates, LLC
Robert
Gottlieb, 857-891-9091
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
